Effect of Rifampicin on the Pharmacokinetics of BI 409306 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed Sequence Trial)
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs BI 409306 (Primary) ; Rifampicin
- Indications Alzheimer's disease; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.